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1032-126 Effects of Alcohol Septal Ablation Versus Surgical 
Myectomy on the Cardiac Conduction System
Deepak R. Talreja, Rick A. Nishimura, Steve R. Ommen, A. J. Tajik, David R. Holmes, 
Mayo Clinic, Rochester, MN
Background: Permanent pacing for heart block is a complication of current septal reduc-
tion procedures for patients with hypertrophic cardiomyopathy (HCM). These procedures
have separate anatomic effects on the conduction system and knowledge of these differ-
ences may identify patients at higher risk for heart block.
Methods: We examined medical records of patients with HCM who underwent percuta-
neous alcohol-septal ablation (ASA, n=52) or surgical myectomy (SM, n=131) at the
Mayo Clinic from July 1999 through August 2003. Pre- and post-procedural electrocardio-
grams were compared.
Results: Of the 52 patients who underwent ASA, 5 (8%) were paced before the proce-
dure and were excluded from further analysis. Of the 6 (13%) who required permanent
pacing after ASA, 2 had LBBB prior to the procedure and an additional 3 had LAD with
increased QRS duration. Of the 131 pts who underwent SM, 13 were excluded due to
prior pacing. Of the 8 patients (7%) who required permanent pacing after SM, 3 of these
had RBBB prior to the procedure. The right bundle was affected in 47% of patients after
ASA and 4% of patients after SM while the left bundle was affected in no patients after
ASA and 42% of patients after SM.
Conclusion: ASA selectively affects the anterior septum resulting in RBBB, while SM
produces an endocardial lesion in the inferior septal region that is more likely to result in
LBBB. Therefore, patients with baseline RBBB are more likely to need long-term pacing
after SM while those with LBBB are more likely to need pacing after ASA. 
1032-127 Regression of Hypertrophy in Remote Myocardium After 
Percutaneous Transluminal Septal Myocardial Ablation 
in Hypertrophic Obstructive Cardiomyopathy: A 
Magnetic Resonance Imaging Follow-Up Study
Willem G. van Dockum, Marco J.W Gotte, Aernout M. Beek, Folkert J. ten Cate, Jurrien 
M. ten Berg, Mark B.M Hofman, Cees A. Visser, Albert C. van Rossum, VU University 
Medical Center, Amsterdam, The Netherlands, Erasmus Medical Center, Rotterdam, The 
Netherlands
Background: Percutaneous transluminal septal myocardial ablation (PTSMA) in symp-
tomatic patients with hypertrophic obstructive cardiomyopathy reduces the left ventricular
(LV) outflow tract obstruction and decreases LV wall stress. The purpose of this study
was to evaluate the early effects of PTSMA on regional myocardial thickness and
regional myocardial mass with MRI. 
Methods: In twenty-seven patients (age 52±15 years) MR imaging was performed at
baseline and at one and six-month’s follow-up after PTSMA. With contrast-enhanced
(CE-)MRI infarct size and location were determined. Changes in regional wall thickness,
LV volumes and regional myocardial mass were evaluated using cine imaging.
Results: After PTSMA, no infarction-related hyperenhancement was found outside the
target area using CE-MRI. In patients with a successful gradient reduction (n=24), end-
diastolic septal thickness at the infarct site decreased from 2.0±0.4 cm at baseline to
1.3±0.2 cm and 0.9±0.3 cm at 1 and 6 month’s follow-up, respectively (p<0.001). Also the
anterior, lateral and inferior wall thickness decreased significantly at both 1 and 6 month’s
(p<0.05 and p<0.001, resp.). As LV end-diastolic volumes remained unchanged, and LV
end-systolic volumes increased (p<0.001), ejection fraction decreased from 69±5% to
65±5% at 6 month’s (p<0.001). Total LV myocardial mass decreased from 207±52 to
190±49 g (– 8%) and 165±42 (– 20%) at 1 and 6 month’s, respectively (p<0.001). Septal
mass decreased from 73±22 g to 64±19 g (– 12%) at 1 month and to 57±17 g (– 22%) at
6 month’s (p<0.001). The reduction of remote mass was significant at both 1 and 6
month’s follow-up (p<0.001), indicating early LV remodeling.
Conclusion: Septal ablation therapy in HOCM results in early LV remodeling with
increased end-systolic volumes, normalization of EF, and regression of the remote myo-
cardial hypertrophy.
1032-128 AMP Kinase Disease in Hypertrophic Cardiomyopathy: 
Evidence for a Multisystem Storage Disorder
Ross T. Murphy, Jens Mogensen, Ajay Bahl, Toru Kobu, Janice Holton, Perry M. Elliott, 
Kate McGarry, William J. McKenna, The Heart Hospital, London, United Kingdom
Background: Mutations in the gene for AMP-activated protein kinase (PRKAG2) have
recently been described as disease-causing in hypertrophic cardiomyopathy (HCM). We
set out to investigate the prevalence and clinical expression of AMP Kinase disease in
patients with typical and atypical HCM drawn from a large clinical cohort of 1468 HCM
patients.
Methods: Mutation analysis of PRKAG2 was performed by fluorescent SSCP analysis
and direct sequencing of abnormal conformers. Clinical evaluation including electrocar-
diography (EKG), echocardiography, Holter monitoring and metabolic exercise testing
was performed. Skeletal muscle biopsy was performed where appropriate.
Results: Mutation screening of unselected and selected cohorts of HCM patients identi-
fied only one de-novo mutation, in addition to two previously identified families with
PRKAG2 mutations.
Mean age at clinical diagnosis in the 45 gene carriers was 24 years (median 20, range 9-
55). Symptoms of palpitations, dypspnea, chest pain or syncope were present in 31
(69%) of gene carriers. Seven patients (15%) complained of myalgia and had evidence of
proximal myopathy. The EKG pattern was characterized by left ventricular hypertrophy
(LVH) with bizarre QRS pattern, short PR interval, and/or delta waves. Disease pene-
trance defined by EKG abnormalities was 100% above the age of 18. Thirty-two of 41
adults (78%) had left ventricular hypertrophy on echocardiography (mean maximal wall
thickness: 21mm (range: 13-40).
Survival rate was 91% at a mean follow-up of 12.2 years. Progressive conduction dis-
ease was identified leading to pacemaker implant in 17/45 (38%) mutation carriers at a
mean age of 38 years. Of patient > 18 years at first assessment, there was slowly pro-
gressive LVH on echocardiography in 78%. Skeletal muscle biopsy showed excess mito-
chondria and ragged red fibres with glycogen accumulation. Functional muscle studies
are discussed.
Conclusions: Disease pattern is characterized by progressive conduction disease requir-
ing pacing, progressive cardiac hypertrophy and includes extra-cardiac manifestations
such as a skeletal myopathy, consistent with a systemic metabolic storage disease.
1032-129 By Relieving Obstruction, Disopyramide Increases 
Extent and Duration of Systolic Shortening in 
Obstructive Hypertrophic Cardiomyopathy: A Doppler 
Tissue Imaging Study
Shrikanth P. Upadya, Ivan Barac, Vilma Casteneda, Michael Passick, Farooq A. 
Chaudhry, Mark Sherrid, St. Luke- Roosevelt Hospital, New York, NY
Background: Disopyramide relieves left ventricular outflow (LVOT) gradient and
improves symptoms in obstructive hypertrophic cardiomyopathy(OHCM). Doppler tissue
imaging (DTI) has shown premature cessation and reduced extent of longitudinal systolic
shortening in OHCM which corresponds to a mid-systolic drop (MSD) in left ventricle (LV)
ejection velocity- the lobster claw abnormality. Changes in DTI after disopyramide treat-
ment in OHCM are unknown.
Methods: Eleven patients with OHCM who were treated with disopyramide(age=68 ±15,
8 females) were selected as systolic gradient decreased to less than 60 mm Hg after 4.7
+ 4.7 days. Long axis DTI was performed from the apex to record the mitral annular
velocities at the basal septum and the basal lateral wall. Offline measurement of DTI
determined the velocity time integral (VTI), peak systolic velocity, and duration of systole,
calculated as the time from the beginning of the QRS to the end of the systole on the DTI
trace. Results: Results are shown in Table. After disopyramide reduction of gradient,
there was significant increase in the VTI of the septum, VTI of the lateral wall and the
septal systolic duration. This corresponds to a disappearance of the MSD.
Conclusions: Relief of obstruction causes an increase in the duration and excursion of
the systolic longitudinal LV contraction. This confirms that MSD is caused by the prema-
ture cessation of longitudinal shortening in mid-systole and that the abnormalities of
shortening are reversible.
HCM with GNT
Pure apical HCM
(n=14)
Mixed form
(n=5)
ASH with GNT
(n=24)
Age at diagnosis
(years)
54+-16 61+-12 52+-14
Male 93% (13) 100% (5) 83% (20)
Family history 7% (1) 40% (2) 38% (9)
Max LV thickness
(mm)
18+-2 18+-2 20+-5
NYHA III-IV 0% (0) 0% (0) 7% (2)
Table
Parameters Pre- treatment Post- treatment p value
Heart rate 76 ± 20 63 ± 12 0.029
LVOT gradient 123 ± 41 14 ± 20 0.00002
Mitral regurgitation
1.2 ± 1 0.55 ± 0.5
0.026
Septal VTI (cm)
1.25 ± 0.5
1.85 ± 0.42 0.00005
PSV- Septal (cm /sec.) 8.67 ± 1.85 7.66 ± 1.26 0.22
Sytolic duration - Septal (msec.) 274 ± 9.9 356 ± 5.2 0.027
Lateral VTI (cm) 1.65 ± 0.33 1.91 ± 0.42 0.005
PSV- Lateral (cm/sec.) 8.57 ± 1.78 9.79 ± 2.4 0.16
Systolic duration ( msec.) 386 ± 4.6 392 ± 4 0.15
